STOCKHOLM , July 23, 2024 /PRNewswire/ — Diamyd Medical received encouraging feedback from the U.S. Food and Drug Administration (FDA) regarding an Accelerated Approval pathway for its immunotherapy, Diamyd®, for treating patients with Stage 3 Type 1 Diabetes carrying the genotype HLA…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.